Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of new human CYP2C19 alleles (CYP2C196 and CYP2C192B) in a Caucasian poor metabolizer of mephenytoin.

The Journal of pharmacology and experimental therapeutics - 1 Sept 1998

Ibeanu G C, Goldstein J A, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem B I, Blaisdell J

Abstract excerpt

A genetic polymorphism in the metabolism of the anticonvulsant drug S-mephenytoin has been attributed to defective CYP2C19 alleles. This genetic polymorphism displays large interracial differences with the poor metabolizer (PM) phenotype representing 2-5% of Caucasian and 13-23% of Oriental populations. In the present study, we identified two new mutations in CYP2C19 in a single Swiss Caucasian PM outlier (JOB 1)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 Enzyme System

Share to Mephenytoin

Share to Mixed Function Oxygenases

Share to Mutagenesis, Site-Directed

Share to White People

Source

Identifiers

PMID: 9732415

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.PMID 9732415Read ↗

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.Semantic proximity Read ↗

An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.Semantic proximity Read ↗

Identification and functional characterization of new potentially defective alleles of human CYP2C19.Semantic proximity Read ↗

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.Semantic proximity Read ↗

Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.Semantic proximity Read ↗

Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole.Semantic proximity Read ↗

Biochemistry and molecular biology of the human CYP2C subfamily.Semantic proximity Read ↗

Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.Semantic proximity Read ↗

Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation.Semantic proximity Read ↗

Novel mutations in the cytochrome P450 2C19 gene: a pitfall of the PCR-RFLP method for identifying a common mutation.Semantic proximity Read ↗

Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.Semantic proximity Read ↗

Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized MedicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.